EAPM - 2nd European Alliance for Personalised Medicine Congress 26 - 28 NOVEMBER 2018
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
2018
EAPM
M I L A N
2nd European Alliance for
Personalised Medicine Congress
26 - 28 NOVEMBER 2018
2018
EAPM
M I L A N
2018
EAPM
M I L A N
Table of Contents
Invitation to Participate................................................................................................................................ 4
About the Venue............................................................................................................................................. 4
About EAPM 2018............................................................................................................................................6
About Milan.........................................................................................................................................................7
Local Organiser Scientific Committee - LOSC..................................................................................8
Programme.........................................................................................................................................................9
Plenary - Presidential Sessions Overview.......................................................................................... 12
Key Dates........................................................................................................................................................... 13
Tracks Overview............................................................................................................................................. 14
Who will attend?............................................................................................................................................ 18
3
2018
EAPM
M I L A N
Invitation to participate
Milan Congress on the right track for EAPM Aims and Objectives
personalised medicine
The European Alliance for Personalised
The European Alliance for Personalised Medicine (EAPM) is a Brussels-based
Medicine (EAPM) will hold its second annual organisation consisting of patients, academics,
Congress at the end of November, this time in healthcare professionals, researchers, industry
the Italian city of Milan. representatives and more, from 40 different
stakeholder groups.
The event will take place in the Lombardy
capital from 27-30 November at the MiCo - Its goal is the integration of personalised
Milano Congressi - five minutes from the centre medicine into Europe’s healthcare systems.
of the city. The Alliance meets regularly with legislators/
regulators to explain the stakeholder
The prestigious gathering will complement the first
perspective from a consensus-based platform.
annual Congress (held in Belfast last November).
The Alliance aims to:
The event in Northern Ireland’s capital saw
650 delegates plus more than 200 speakers. Establish a leadership position in
These were drawn largely from patients personalised medicine
representatives (22%), policy makers/politicians Position personalised medicine within the
(35%), 30% of attendees and speakers had broader context of personalised Healthcare
research and/or scientific backgrounds and
industry representatives accounted for around l Help to ensure the understanding of
15% of those present. personalised healthcare by patients,
professionals and policymakers
These statistics were largely mirrored by
the exhibitors at the Congress and the Help shape EU policy discussions and create
aforementioned percentages are expected to be incentives for personalised medicine
echoed in Milan. Help shape a favourable reimbursement
As happened in Belfast, EAPM is working environment for personalised medicines and
closely with a much-esteemed local organising companion diagnostics
committee, who are working hard ‘on the ground’ Bring together healthcare planners, medical
to make the Congress a great success. We are professionals, research organisations, NGOs,
especially delighted to be working with Lombardy industry any other stakeholders in the
Region, Italian National Institute of Health, continuum
Humanitas Hospital and University of Milan.
Ensure a multi-disciplinary approach
Among the most successful elements in Belfast
were the daily newsletters and the non-stop Promote ‘outreaching’ to regulatory
Twitter content, highlighting the main events authorities, EU politicians, national
of the day and previewing many of the sessions politicians and EU/national media
upcoming. This strategy will be used again in Develop a comprehensive and collaborative
Milan giving the Congress plus its sponsors and approach to achieve coordination
speakers the highest profile possible.
The venue
Launched in 2002 and doubled in size in 2005, the Featuring two plenary rooms, one with seating for
current extension places MiCo - Milano Congressi 4,000 and the other for 2,000 and an Auditorium
among the largest conference facilities in Europe that seats 1,500, it is the ideal venue for large-scale
and worldwide. Designed by Mario Bellini, it’s able to performances and for international conferences
accommodate up to 18,000 people in 70 or so fully requiring a large number of rooms. In the same way,
appointed conference rooms with permanent control the exhibition halls offer 54,000 sq.m of exhibition
booth. space and can also be set up as extra plenary rooms
accommodating more than 5,000 people.
4
2018
EAPM
M I L A N
Top topics Interaction is key…
The themes and tracks at Milan will see There will be more than 35 networking
Congress debate, among other things, opportunities throughout the week of the
diagnostics and medical devices and Congress, and EAPM is in partnership with
translational research. These will run alongside a major organisation in order to develop the
sessions covering personalised medicine in content and structure around each theme,
hospitals and a look at the work of various which will run as separate tracks.
regions across the EU in the personalised
One of the over-arching aims, as ever, is to
medicine field. The latter track will run across
also allow for interaction between the different
three days.
disease and policy areas, allow delegates to gain
Also featured will be a two-day track covering a greater depth of knowledge into barriers in
many aspects of men’s health, including the field of personalised medicine.
awareness raising, plus sessions dealing with
On top of this, Congress will offer up valuable
hospitals and specifically patients.
evidence and stakeholder opinion on which
To complement the Alliance’s annual summer policy makers can base their decision making on
school for healthcare professionals (HCPs), such how better to integrate personalised medicine
as general practitioners, a three-day ‘winter into the EU’s healthcare services.
school’ will also be a feature of the Congress.
The event will provide a large and effective
This is specific to the education of HCPs in that
‘space’ to allow for such the meeting of minds
if personalised medicine is to be in line with the
and expertise and will act as a vital one-
EU and Member State principle of universal and
stop-shop for top-level discussion and the
equal access to high-quality healthcare, then
formulation of real action plans.
clearly it must be made available to many more
citizens than is currently the case. In the region of 850 delegates are expected to
attend, with a focus on regional representations
Also featured at the Congress will be coverage
(including Member State and regional agencies,
of our proposed and very ambitious Million
such as medical authorities, regional HTA
European Genomes Alliance (MEGA) over two
agencies, notified bodies and data authorities).
days, as well as aspects of artificial intelligence.
Other topics will see a focus on diabetes, EU-, national- and regional-level politicians will
patient perspectives, access and early diagnosis. be present to complement the regional focus
on research and innovations in health. They will
The role of SMEs in modern-day medicine will
be joined by experts from scientific centres,
also come under the Congress spotlight at the
scientific hospitals and research centres.
November event in a track that covers two days.
Also attending will be legislators and
This track-based Congress system allows
policymakers in the form of MEPs and
separate stakeholders in different arenas to
Commission officials, given that a key aim of
concentrate on their fields. But, of course,
the Congress is to set the agenda for European
these diverse groups also allow for necessary
healthcare during the coming years.
cross-fertilisation, interaction and sharing of
ideas. For more information on
the agenda, click here
The Congress will also play host to nine
Presidential sessions across the week.
Like the first edition and several Presidency
conferences, the Milan Congress will
bring together leading experts in the
arena drawn from patient groups,
payers, healthcare professionals plus
industry, science, academic and research
representatives.
5
2018
About EAPM 2018
EAPM
M I L A N
More than 1000 Life Sciences thought fit-for-purpose and reflect the swiftly changing
world of medicine, are vital. Hence our continued
leaders will convene at the second annual
EAPM Congress, to be held at the MiCo - Milano interaction with MEPs, Commissioners and
Congressi - in Milan this November 27-30. Member State health leaders.
As it did last year in Belfast, the annual EAPM also aims to showcase developments and
event will bring together key audiences who new ideas at Congress. For example, development
contribute to the vast programme content and of major initiatives in genomics and personalised
vital knowledge exchange. medicine is a global trend with significant
investments being committed, for example by the
Don’t miss the opportunity to join large governments of the US and China.
numbers of industry professionals, government
regulators, patients, academia, and exhibitors to In Europe the most comprehensive initiatives,
drive insights to action. encompassing clinical implementation, research
and enterprise, are being seen in countries such
More than ever this year, a focus will be on as the UK (100,000 Genomes Project) and
the upcoming European Parliament elections France (Médecine Génomique 2025).
and the installation of a new College of
Commissioners, tasked with devising and It is important that Europe remains competitive
implementing regulatory frameworks in all in this field given the resulting health and
areas, including certain aspects of health. economic benefits and EAPM’s plans for a
Million European Genomes Alliance (MEGA)
More than 700 MEPS will be elected next would be synergistic with the national aims,
summer and the Commission will also have a projects and activity of participating Member
new president as Jean-Claude Juncker steps States and provide structures and a network
down. that can move research to clinical practice and
One of the goals of Congress is to engage commercial enterprise, putting these countries
politicians and lawmakers in the fast-growing at the forefront of personalised medicine
field of personalised medicine, and deliver globally.
political asks through our consensus-based MEGA is part of just one of many tracks to be
process. covered in Milan including innovation, education,
Europe needs to grasp the fact that health modern hospitals, funding, guidelines and more.
equals wealth and that investment in research Click here for more information on the agenda.
and innovation, alongside laws and rules that are
Why you should attend
Milan will see a multi-stakeholder driven Congress with patients at the centre
The EAPM Congress is a neutral organisation providing thought leadership content and a global platform
for healthcare product development and knowledge exchange designed to drive change and improve
outcomes.
It’s an opportunity to learn more the scientific, research and policy development in personalised medicine,
its huge potential and how it can change the lives of millions of patients for the better
Attendees have the chance to hear the opinions of experts first hand and engage with European, national
and regional pliticians, as well as respond to and pose questions on the day
Also, those present will have the chance to understand how an integrated, coherent, cost-effective and
cohesive health strategy will impact on systems and the standard of care in individual Member States
Congress is a valuable opportunity to see into the minds of other stakeholders, understand their issues and
find out what they really feel they need from you
And it represents an excellent chance to network with (and be interviewed by) health journalists. Also, to
meet industry leaders, cutting-edge scientists and all other personalised medicine stakeholders from across
the EU
Click here to register.
6
2018
More on Milan
EAPM
M I L A N
On top of this, the city is home to two of
Europe’s most successful football teams, AC
Milan and Internazionale (Inter Milan), who share
the famous San Siro stadium.
The MiCo venue features welcoming conference
halls and well linked spaces. It is within easy
reach of the city’s finest attractions, such as
Leonardo’s Last Supper, which is less than five
EAPM is delighted to have the famous and minutes’ walk away.
elegant city host the Congress. Among other
things, Milan is renowned for healthcare, The ‘old own’ is just one Metro stop away: along
research, the arts, commerce, with the Duomo and the Sforza Castle.
design, education, entertainment, Milan is the powerhouse of Italy: it
fashion, finance, and tourism. It is produces 10% of the country’s GNP;
home to Italy’s Stock 25% of domestic research, it
Exchange as well as is home to 10 universities
the headquarters of and every year it attracts
large national and over 4 million tourists.
international banks. The Romans called it
Given its prowess “Mediolanum” due to its
in healthcare, Milan position at the centre of the
will act as the main communication routes of
perfect venue for the time. Today, it is still one
the personalised of Europe’s most accessible
medicine Congress. and welcoming cities:
Personalised 200 destinations linked
medicine is, of by 364,000 flights a year,
course, in the news 380 hotels with over 21,000
more-and-more often guest rooms. An immense
these days, with its goal of giving system that comprises not only
the right treatment to the right manufacturing, but also services, culture,
patient at the right time. entertainment, art, cinema, television, NGOs,
fashion, sport and research. Milan has ancient
Milan has the third-largest economy in origins; it was the capital of the Western Roman
respect of European cities and is considered Empire and boasts a unique, world-famous
one of the ‘Four Motors for Europe’. It acted artistic heritage, of which the best known is
as the de facto capital of the Western Roman Leonardo da Vinci’s Last Supper. Today the
Empire from 286 to 402 AD. international centre of fashion and design, and
Modern day Milan is considered the fashion a shopper’s paradise, Milan is a vibrant, trendy
and design capital of the world hosting city, brimming with things to do and with a
several international events and fairs, not least constantly changing scenario of clubs, bars
among them the Milan Fashion Week and the and restaurants. All this against a truly enviable
Milan Furniture Fair. backdrop, Lombardy: dotted with charming
cities of art, it is the region with the greatest
The city receives around eight million expanse of natural parks and magnificent lakes –
overseas visitors each year. These tourists such as Lake Como – surrounded by mountains
are attracted by Milan’s museums and art that attract numerous hikers and skiers. Without
galleries, hosting some of the most important forgetting the rich flavours of Lombardy’s
collections in the world, including important internationally renowned foods and wines. All
works by Leonardo da Vinci and other this just over two hours from Venice, Florence
famous names. and Genoa.
7
2018
EAPM
M I L A N
Local Organiser Scientific Committee - LOSC
David Byrne, Co-Chair,
European Alliance for Personalised Medicine
Gordon McVie, Co-Chair,
European Alliance for Personalised Medicine
Denis Horgan, Executive Director,
European Alliance for Personalised Medicine
Local Committee
Walter Ricciardi Paolo Casali
Italian National Institute of Health (Istituto Head of the Adult Mesenchymal Tumour
Superiore della Sanità); Institute of Public Medical Oncology Unit, Istituto Nazionale
Health, Università Cattolica del Sacro Cuore, Tumori, Milan
Rome, Italy
Monica di Luca
Giulia Veronesi Full Professor, Department of Pharmacological
Robotic Thoracic Surgery, Humanitas Research and Biomolecular Sciences, University of Milan
Hospital
Marina Gerini
Filippo de Braud General Director, Fondazione Regionale per la
Professor, Medical Oncology, University of Milan Ricerca Biomedica
Gennaro Ciliberto Ivana Cattaneo
Scientific Director, IRCCS, Instituto Nazionale Public Affairs Director, Novartis Oncology
Tumori “Regina Elena, Rome, Italy Europe
Gabriella Pravettoni Francesco de Lorenzo
Professor of Cognitive and Decision Making President, European Cancer Patient Coalition
Psychology, University of Milan
Stefania Vallone
Mario Pazzagli President, Lung Cancer Europe (Luce)
Professor, Dept. Clinical Physiopathology, O.U.
Clinical Biochemistry, University of Florence Giovanni La Via
Member of the European Parliament
Giovanni Codacci Pisanelli
Assistant Professor in Medical Oncology, Paolo Marchetti
University of Rome “La Sapienza” Full Professor of Medical Oncology, Sapienza
University, Rome
Fedro Peccatori
Director of the Fertility and Procreation Unit,
Division of Gynecologic Oncology, Department
of Gynecology, European Institute of Oncology,
Milan
8
2018
Programme
EAPM
M I L A N
Day 1
Access
Education Diagnostics/
Men’s Genomics/ and
Regional – Winter Medical
Health School Devices
MEGA Early
Diagnosis
09:00 - 10:15 Parallel Session
Role of Putting the Opening Regulatory Perspectives Are Current
Coordinating Spotlight Session: Framework on Genomics Frameworks
Support On Men and Objectives of for Useful to
Action Men’s Health the Winter Companion Capture the
Through Summer Diagnostics Value of P.M.
Funding School: and Medical Technolo-
Mechanisms Diagnosis Devices gies? Are
and Decision other
Making Frameworks/
Frameworks Methodolo-
for Family gies
Physicians Required?
and General
Practitioners
10:15 - 10:45 Networking and Exhibition
10:45 - 12:00 Parallel Session
Structural Men’s Session I: Reimburse- What can Value from
Funds to Health as an Shared Ment and Genomics the Economic
support Investment Diagnosis Financing do Now? Perspective
Infrastruc- and Decision- Framework
tures for the Making: for
Personalised Patient/ Diagnostics –
Healthcare Physician Medical
Era Communica- Devices
tion
Opening Plenary Presidential Session –
12:15 - 13:15
“Forward as one – Europe as a Global Player”
13:15 - 14:15 Lunch and Networking and Exhibition
Presidential Session – “Advancing Europe’s Healthcare – Patients &
14:15 - 15:30
Economy”
15:30 - 16:00 Networking and Exhibition
16:00 - 17:15 Parallel Session
Private Accessing Session II: Value of Implementa- Value from
Investment to Health Emerging Diagnostic tion of Organiza-
Drive Forward Services Screening & Information Genomics tional
Healthcare Diagnostic (Vodi) from into Perspective
Tools to Concept to Healthcare Context
Facilitate Reality Systems Matters
Early
Diagnosis of
Disease
17:30 - 18:30 Presidential Session - “New Research in Personalised Medicine”
19:00 - 20:30 Welcome Reception - “60 years of the Rome Treaties”
9
2018
EAPM
M I L A N
Day 2
Education
Genomics/
Regional Hospital – Winter SMEs Diabetes
MEGA
School
08:00 - 08:30 Networking and Exhibition
08:30 - 09:45 Parallel Session
Regional Guidelines Session III: SMEs Million Ensure New
Innovation For The Individualizing Executive European TID Therapies
in Nordic Implementa- Clinical Workshop Genomic are Safe and
Countries tion of PM In Decisions – Session I: Alliance Effective
the Clinical For Elderly Go/No Go: (MEGA) –
Setting Patients Framework Bringing
with Multiple to Prioritize Innovation
Chronic Market Entry into
Conditions Healthcare
systems
Parallel Session
10:00 - 11:15 Regional The Role of Session IV: SMEs Why Should Promote
Innovation Data Sharing Pathways for Executive the EU Take a Access to TID
in Central Within and Diagnosing Workshop – Lead? Therapies and
European Among Rare Diseases Session II: EU Technologies
Countries Hospitals Commercial
Funding
Opportuni-
ties for SMEs
Presidential Session -
11:30 - 12:45
“Facilitating access for todays diseases”
12:45 - 14:00 Lunch and Networking and Exhibition
14:00 - 15:15 Parallel Session
Regional Value Based Session V: SMEs Pillars to Protections
Innovation in Indicators to Digital Tools Executive Realize for Pre-
East Europe Measure the to Connect Workshop – MEGA existing
Countries Impact of with Patients Session III: Conditions
Research into Pharma
Clinical Data Collabora-
tions: What
are the
tradeoffs?
15:30 - 16:45 Parallel Session
Regional New Session SMEs Public- Evaluation of
Innovation in Opportunities VI: Poly- Executive Private New Therapies
Mediterra- for Healthcare pharmacy: Workshop Collaboration
nean Member Communica- Prioritizing – Session
States tion Medical IV: Early
Treatments Dialogues:
Engaging EU
Regulatory
Agencies
Presidential Session – Dialogue with CEOs:
17:15 - 18:45 “From Here to 2025: Personalised Medicine
and Healthcare for an Immediate Future”
10 20:30 - 22:30 Presidency Dinner2018
EAPM
M I L A N
Day 3
Education
Artificial Translational
Regional Patient – Winter SMEs
Intelligence Research
School
08:00 - 08:30 Networking and Exhibition
08:30 - 09:45 Parallel Session
Access Biomarkers Session VII: SMEs Artificial Prevention
Accelerated Health Redefining Executive Intelligence: – Reducing
Initiative Literacy the Role Workshop – Here & Now Harmful
of Family Session V: Impact
Physicians Early of Future
Through Use Dialogues: Diseases
of EHR’s Engaging Local
and Artificial Reimburse-
Intelligence ment
Agencies
10:00 - 11:15 Parallel Session
Better and Ensuring Session VIII: SMEs Frameworks Profiling –
Common that Patient Tools to Executive to Empower Opportunities
Guidelines Preferences Individualize Workshop – the to be Seized
on Various are Valued Clinical Session VI: Healthcare
Diseases when Decisions for Case Study: Is Community
Assessing HCP’s in the Localization
new Era of Co- Scalable?
Treatments mordities &
Survivorship
11:30 - 12:45 Presidential Session –
“Interfacing with Public Policy Makers”
12:45 - 14:00 Lunch and Networking and Exhibition
14:00 - 15:15 Parallel Session
Recent Improving Session SMEs Public Policy Therapeutics
Advances in Health IX: Recent Executive Considera- – Matching
Rare Disease Literacy of Advances in Workshop – tions Conditions
Era Immuno- Personalised Session VII: with
Oncology Medicine Case Study: Treatments
Therapy Market-
Specific
Idiosyncrasies
that SMEs
Forget to ask
About?
15:30 - 16:45 Closing Presidential Session - “Who is to do What?”
112018
EAPM
M I L A N
Plenary - Presidential Sessions Overview
Opening Plenary Presidential Session – modernisation. Individual responsibility in risk
“Forward as one – Europe as a Global Player” reduction and cost sharing/insurance is foreseen
to develop. The medical structures and citizen
Whether it is post-Brexit growth in the UK involvement will also need development to
or resilience in China, improved healthcare optimise the best use of the new possibilities.
supports economic activity.
Focus on research into new medicines and
A healthier Europe will mean citizens spending cutting-edge treatments is key and this will
less and less time in hospitals under expensive already in the shorter run create jobs – whether
treatment regimes, often at a direct cost to they be in research itself, education, design and
the taxpayer, and it will also mean that people manufacture of in-vitro products or within the
receiving the right treatment at the right time pharmaceutical industry.
are more able to stay in the workplace, thus
generating wealth rather than whittling it away.
A shift towards preventative medicine will Research Frontiers in Personalised
reduce costs still further. A focus on research Medicine - from Local to Global
into new medicines and cutting-edge
Europe’s and the international research
treatments will also create jobs – whether they
landscape remains too fragmented. A lack of
be in research itself, education, design and
critical mass in many research centres means
manufacture of in-vitro products or within the
not enough patients, biological materials,
pharmaceutical industry.
technological resources or competences.
If Europe is in the vanguard of developing
Wider collaboration and better infrastructure
new ways of keeping citizens healthy, it will
would help: technical platforms for genomics
inevitably attract investment from outside of the
and other specialty disciplines, screening
bloc.
facilities for new pharmaceutical agents,
The road to better health must have biobanks for tissues and biofluids, quality-
personalised medicine as its destination. This assured patient registries...
innovative method of treating patients utilises
So too would better resources, for prospective
research, data and up-to-the-minute technology
validation of biomarkers that may be predictive
to provide better diagnostics and follow-up for
for treatment, networks on biostatistics,
citizens than is currently the case.
epidemiology and outcomes research.
With the backing of the European Union,
This session will present the leading
Europe can work towards building a healthy and
developments in the area from the oncology,
wealthy Europe, one worthy of its stated goals
neurology and diabetes.
for generations to come.
Presidential Session – “Advancing Europe’s Presidential Session - Facilitating access
Healthcare – Patients & Economy” for today’s diseases
European Union governments and healthcare
Personalised healthcare will need to start with
providers have been seeking to maximise the
prevention to be truly successful and individual,
value for money that they can obtain from the
it will move from disease management to
acquisition of new treatments for patients.
health management which will change the cost
structures and prevent loss of quality life and Consequently, there is a large awareness
generate wealth. of the limits that can be placed on patients
with regards to having to make financial
In order to be effective in personalised medicine,
contributions to their healthcare needs. Payers
and specifically prevention, the way therapy is
are now increasingly likely to deny or severely
approved and subsidised will need significant
12Key Dates 2018
Call for Abstracts - March 19th, 2018
EAPM
Open Registration - March 19th, 2018 M I L A N
Opening of EAPM Annual Personalised Medicine
Congress, Nov. 26th, 2018
restrict the use of advanced therapies when Innovative approaches treatment guidelines,
there is no clear or exceptional economic value and to training and education, will equip
for the broader population as they seek to cut healthcare professionals with new skills and
costs and decrease public spending and debt. knowledge, and overcome reticence by clear
demonstration of advantages among those
Current models have been based on medicines
hesitant to adopt new approaches.
designed to treat an entire patient population,
and the economic value of a specific medicine And radical changes in thinking at the highest
has traditionally been analysed through a policy level in relation to public health generally
comparison with other treatment alternatives or will enhance the measurement of value for
palliative care. health interventions and adapt payment
systems accordingly. All of this will require
This session will examine different strands of
agreement on standards, and improvements to
this issue.
regulatory pathways, as well as an appropriate
regulatory and medical framework.
Presidential Session – Dialogue with CEOs:
“From Here to 2025: Personalised Medicine Closing Presidential Session
and Healthcare for an Immediate Future”
The evidence of the merits of personalised
A massive improvement in the health of medicine is already ample. The potential is
Europe’s citizens is within reach – but making huge. The benefits are there for the taking for
it happen faces challenges that are as much patients, citizens and society, and will bring new
political as technical. levels of satisfaction to professionals working in
Scientists, technologists, physicians and health the health domain.
economists have devised innovative pathways Why, then, is its development and exploitation
to boost the health status of individuals and so slow, particularly in Europe?
to make healthcare systems more sustainable.
Advanced personalised health is no longer a Personalised medicine is the test-case for how
science-fiction vision. It is a tangible possibility. far health systems are capable of a rational
and reasoned response to opportunity. It is
What is needed now to turn vision into reality also a test-case for how far the supporters
is a clearer understanding among Europe’s of personalised medicine are able and willing
policymaker and decision-takers about what is at to come together in a joint effort to drive the
stake: about the gains that can be made with the process that can induce constructive change.
right actions, and equally about the opportunities
that might be squandered with the wrong ones. In some areas, the EU has had a strongly
supportive role in healthcare. The resulting
This session will feature leading politicians and coordination, to develop science, to translate
CEOs. innovation, to systemise marketing authorisation
requirements for medicines and to facilitate
quality testing and trials has shown a positive
Presidential Session – “Interfacing with aspect of the EU, and should serve as
Public Policy Makers” inspiration and encouragement for more joined-
up approaches to tackle new challenges.
The innovative quality of personalised care
demands links to other areas of innovation - If the will to work together on personalised
notably in the use of data, bio-banking, next medicine can be found, a new horizon for health
generation sequencing, screening, advanced in Europe can be reached. The journey can
imaging, biomarkers and more sophisticated reach its destination by 2025. But the benefits
analytics, sharpening the impact of R&D and early can accrue as from today.
diagnostics, all linked to the digitisation of health.
132018
EAPM
M I L A N
Tracks Overview
Regional track: From innovation to in evaluating the risk and benefits of therapies
implementation recommended by other specialists. This
program will address the critical role that GP/
Today’s approach to personalised healthcare FPs play in advancing personalised medicine
remains sub-optimal. The opportunities are and how different healthcare systems should
obvious: physicians increasingly identify the facilitate the role of these physicians.
root causes of disease and match patients to
the therapy that can target a specific type of
disease or genetic mutation, with diagnostic Men’s Health in the EU: A
tests and tools increasingly driving treatment Personalised Approach
decision-making.
Men’s health is complex and multifaceted,
The understanding of disease advances all the
and it moves well beyond those male-specific
time, with breakthroughs in treatment options
conditions resulting from men’s differing biology
in many non-communicable conditions ranging
with women. Patterns emerging show a marked
from neurological to cardiovascular to diabetes
differences between the health of men and
to respiratory - and to rare haematological
women, and at the same time large disparities
diseases, as well as in cancer, where some 250-
in health outcomes within male populations in
300 identified types and subtypes can now be
each Member State.
identified and targeted.
The extent and depth of the problem of
But there are serious delays in introducing
premature mortality is one of the most striking
innovation into healthcare systems. Therefore,
and worrying findings, especially as it involves
during this track, personalised health experts
nearly the whole spectrum of health conditions.
will present their shared vision on the role,
structure and responsibilities of integrating Men’s greater risk of developing and dying
healthcare into EU healthcare systems at both from nearly all cancers that, biologically, should
regional and national level. affect men and women equally; the high rate of
premature deaths from cardio-vascular disease;
the increased risk from the major communicable
Winter School: Diagnosis and Decision diseases; and the vulnerability of men to
Making Frameworks for Family accidents, are but some of the life-limiting
Physicians and General Practitioners factors impacting on men.
With the emergence of personalized medicine,
patients are increasingly being treated with Medical Devices and Diagnostics
novel treatments by specialist. Due to this
changing paradigm, the role of the family The recently adopted EU Council Conclusions
physician/general practitioner is evolving to on Personalised Medicine for Patients1 refer
make them critical in screening and diagnosing to personalised medicine as “a medical
patients to ensure that they can benefit model using characterisation of individuals’
from the latest treatments. These shifts are phenotypes and genotypes (e.g. molecular
necessitating that FP/GPs stay updated on the profiling, medical imaging, lifestyle data) for
latest advances across medicine to allow them tailoring the right therapeutic strategy for
to advocate for their patients and address the the right person at the right time, and/or to
many questions asked by Internet-informed determine the predisposition to disease and/or
patients. Considering that many newly available to deliver timely and targeted prevention.”
treatments are more effective when diseases are In this respect, personalised medicine has the
diagnosed and treated early, it is advantageous potential to optimise the timely delivery and
that these physicians diagnose their patients dosing of treatments so that patients can
early to improve outcomes. Also, the FP/GPs receive the most benefit for the least amount of
often act as a trusted advisor to their patients
142018
EAPM
M I L A N
risk and harm, minimising both the unnecessary laws. Other faculty will include representatives
side effects of potentially toxic treatments such from large pharmaceutical companies, patient
as chemotherapy and the delays associated organizations, venture capitalists, and other
with the “trial-and-error” process that many Senior leaders from leading SMEs.
patients endure to obtain the correct diagnosis
and treatment for their condition.
Despite their widely recognised promise, the use
Genomics Track: From Innovation To
of diagnostics in clinical practice across Europe Implementation
is still limited. Healthcare systems in Europe are Next Generation Sequencing technologies
not designed to support personalised medicine provide physicians with the ability to make
approaches and related innovative diagnostic educated diagnoses based on a patient’s
technologies. This is reflected in a lack of genome which will lead to better health
appropriate patient access and pathways for outcomes for rare inherited diseases and cancer.
reimbursing molecular diagnostics.
The technology is out there, but stakeholders
This track will present a policy framework for need to collaborate much better, invest more in
integrating diagnostics into healthcare systems. research and innovation, and deliver again and
again the message that patients are at the heart
of their own healthcare.
SME Executive Workshop:
Prioritization, Funding and Access Genomics is driving precision medicine, which
across European markets is in turn driving massive changes in disease
diagnosis and treatment. With its strong
Target Audience: Senior level managers from tradition of universal healthcare the European
SMEs* - Pharmaceutical, Diagnostic, and Digital Union is in a unique position to reap the
Healthcare companies. resulting quality and costs improvements; this
track will be an opportunity build a plan for
Personalised Healthcare Executives often genomics in European healthcare.
face critical decision junctions on whether
to pursue opportunities outside their home
markets or develop new product offerings to Hospitals of the Future in the Age of
support the next wave of growth in the face Personalised Medicine
of limited resources. As most healthcare –
related products especially therapeutics are University hospitals play an important role as
commercialized globally, these executives front-runners in and catalysts for innovation,
are questioned by their boards and potential as well as promoting best practices and
customers on their plans to commercial contributing to the development of strong local,
products across Europe and whether they plan regional and national economies.
to commercialize directly or with a partner.
The overall aim of University Hospital
This session will provide these senior leaders Association Europe (UHAE) members is to play
essential frameworks to prioritize opportunities an active role in shaping the future of healthcare
across various European markets and to better in the EU, sharing best practices for patient
understand the EU Personalized Healthcare benefit and maximising efforts to drive high-
landscape. The participants will learn about quality research.
unique opportunities to gain additional funding
Personalised medicine is an integral part
and accelerate market access under special
of UHAE approach to improve patient care
EU programs. Also, these executives will
whilst ensuring the sustainability of healthcare
have opportunity to ask questions to market
systems. By placing patients at the heart of the
access and regulatory experts on topics such
system, healthcare services will increasingly
as the new IVD directive and data privacy
deliver the right intervention to the right person
152018
EAPM
M I L A N
at the right time, improving the outcomes But exactly how will AI and robotics define
for patients and cutting down unnecessary modern-day healthcare?
treatments.
During this session, UHAE representatives will
present their shared vision on the role, structure
Defining Value In Personalized
and responsibilities of the hospitals of the Medicine, Sides And Domains
future. The conclusions from this work are the That Define Value From A Holistic
result of an extensive multi-stakeholder expert Perspective.
consultation among UHAE members which was
Personalised medicine approaches, although
presented to the European Commission’s DG
well-known in the past and applied as required
SANTE in June 2018.
by health professionals, have experienced
dramatic changes in their way they address
the conditions and pathologies. Mostly, it has
Finding The Policy Balance For
been due to the launch and application of new
Diabetes Patients technologies and solutions, such as genetics,
Type 1 diabetes is a disease continuum with improvement in the recording of clinical,
specific pre-symptomatic stages with defined environmental and life style data and capacity
risk of progression to symptomatic disease. of the systems to integrate all these data and
provide individual diagnostic and prognostic
Prognostic biomarkers have been developed for profiles for individual patients.
disease staging and for stratification of subjects
that address the heterogeneity in rate of disease This promising landscape is obviously
progression. Using biomarkers for stratification generating a non-deniable change to the way
of subjects at different stages of type 1 diabetes health professionals diagnose, treat and follow-
will enable smaller and shorter intervention up patients and it is clearly impacting the
clinical trials with greater effect size. management of individual patients.
Addressing the heterogeneity of the disease will Having said this, it is noticeably that it has also
allow precision medicine-based approaches to an impact on health care systems’ organization,
prevention and interception of pre-symptomatic budget and outcomes. The issue at this stage
stages and treatment and cure of symptomatic is to determine to which extent existing
disease. frameworks to capture value of technologies
can be directly applied to Personalised medicine
solutions.
Artificial Intelligence Track: From
Innovation To Implementation
Patient Track: From Innovation To
While continual advances in medicine have Implementation
paved the way for more effective treatments,
increasing pressure on healthcare systems is In this modern world of medicine, in which many
reinforcing the need for improved efficiencies. stakeholders are pushing for co-decision on
treatments between patients and their doctors,
Expenses and labour issues are taking their the relationship between the two has never
toll on healthcare quality and accessibility been more important.
worldwide. The increasing prevalence of
Artificial Intelligence (AI) in the sector is poised EAPM is of the opinion that patients should be
to disrupt healthcare systems on a global scale. placed at the centre of their own healthcare
decisions. and empowering the patient is a
AI is a collective term for computer systems fundamental pillar of personalised medicine.
that can sense their environment, think, learn,
and take action. The emergence and increasing While modern medicine, including genetics-
use of AI and robotics will have a significant based technologies, screening programmes,
impact on healthcare systems around the world. imaging, innovative medicines and more, are
162018
EAPM
M I L A N
allowing doctors to target medicines much the barriers that currently exist
more effectively, Europe has issues of bringing
- Empowerment: Providing the infrastructure
innovation into healthcare systems not helped
and tools to deliver a PM-enhanced
by an ageing population.
health system landscape that empowers
Even if there is treatment available it can still be translation of discovery science into new
difficult to get a targeted therapy. We already diagnostic, therapeutic and preventative
know that a patient’s lifestyle and working approaches
situation will, in ideal circumstances, play a
major part in any treatments if the doctor/
patient relationship is operating at optimum
levels. And it is certainly key that the patient is
proactive in asking questions.
This session will deal with the different
paradigms.
Translational Research Track: Realising
the vision of Translational Research
In cancer, targeted approaches such as the use
of Tyrosine Kinase Inhibitors (TKI) in Chronic
Myeloid Leukemia (CML) and Monoclonal
Antibodies (MOAb) in erb-B2 positive
breast cancer, have led to practice-changing
clinical management in these diseases, while
the establishment of a national molecular
diagnostics platform by L’Institute International
du Cancer (L’INCa) in France has underpinned
precise stratification of patients for innovative
personalised medicine therapies.
In Cystic Fibrosis, the use of a companion
diagnostic which recognises a particular
disease-causing mutation in the Cystic Fibrosis
Transmembrane Conductance Regulator
(CFTR) protein, allows selection of patients for
successful therapy with a treatment that targets
this specific mutation. Such approaches are also
shaping the development of new preventative
and therapeutic methods in cardiovascular and
infectious disease.
However, despite the significant advances that
have been made, the undoubted potential can
only be realised by a harmonised research
agenda that enables efficient and effective
translation of scientific innovation. Two critical
pillars will underpin activities:
- Awareness: Understanding the potential
for PM to deliver improved outcomes for
European citizens, the challenges that it
presents to traditional health systems and
172018
Who will attend?
EAPM
M I L A N
More than 1000 delegates (plus over 200 speakers) are expected to
attend including:
• National and regional representatives (medical authorities,
regional HTAs, notified bodies and data authorities)
• Legislators and policymakers (MEPs, EU Commission
experts, national and regional politicians)
• Research experts (Scientific centres,
hospitals and research centres)
• Health economic systems
experts (National and
regional health ministers
and representatives from
payer/reimbursement
authorities)
• The voice of the patient
(Patient groups and experts
advocating giving the right
treatment to the right patient
at the right time)
182018
EAPM
M I L A N
Contact: Denis Horgan EAPM Executive Director
Avenue de l’Armee/Legerlaan 10, 1040 Brussels
Tel: + 32 472 535 104
www.euapm.eu
19You can also read
